An expected surge in generic GLP-1s is anticipated to reshape not only pharmaceutical pricing and access but also the global MedTech ecosystem supporting drug delivery.

Akila Samiiya, Lead Analyst at Beroe and Rahul R Patil, Medzus, break down what the rise of generics means for drug delivery device procurement and what leaders should be doing about it now.

Read the full Pharmaceutical Exec article herearrow-right

Related Reading

Featured Image

14 Aug, 2026

How My Career Journey Has Shaped How I Lead Today

Featured Image

31 Jul, 2026

Conflicts escalate, jet fuel takes a hit. U.S. analysts are confident - for now

Featured Image

23 Jul, 2026

The climate shock that could reshape food costs until 2027